| Not Yet Recruiting | Investigating Participation Patterns Among Stage IV Melanoma Patients NCT06093594 | Power Life Sciences Inc. | — |
| Active Not Recruiting | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer NCT06416085 | University Health Network, Toronto | Phase 2 |
| Active Not Recruiting | Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients NCT05176470 | Richard Wu | Phase 1 |
| Active Not Recruiting | Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health Sy NCT07376317 | Instituto do Cancer do Estado de São Paulo | Phase 2 |
| Withdrawn | Sargramostim (GM-CSF) + PD-1 NCT04703426 | Dana-Farber Cancer Institute | Phase 2 |
| Unknown | Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer NCT04670445 | Massachusetts General Hospital | N/A |
| Active Not Recruiting | A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma NCT04356729 | Elizabeth Buchbinder, MD | Phase 2 |
| Unknown | Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Fac NCT04142931 | Dr. Ronnie Shapira | Phase 1 |
| Unknown | Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhi NCT03385486 | Taiga Biotechnologies, Inc. | Phase 1 |
| Completed | TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma NCT04059224 | Universitair Ziekenhuis Brussel | Phase 2 |
| Active Not Recruiting | Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimet NCT03235245 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Completed | Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma NCT03200847 | University of Colorado, Denver | Phase 1 / Phase 2 |
| Withdrawn | Radiation Use During Vemurafenib Treatment NCT01843738 | University of Utah | Phase 1 |
| Unknown | A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV NCT02990416 | Angimmune LLC | Phase 1 / Phase 2 |
| Completed | Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melano NCT02676869 | Immutep Australia Pty. Ltd. | Phase 1 |
| Terminated | Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients NCT02744209 | Mayo Clinic | — |
| Terminated | Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma NCT02327390 | Case Comprehensive Cancer Center | Phase 1 |
| Withdrawn | Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations NCT02263898 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma NCT02306850 | St. Louis University | Phase 2 |
| Completed | Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations NCT02296112 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Completed | APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Me NCT02166255 | Wake Forest University Health Sciences | Phase 1 |
| Terminated | High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By NCT02203604 | CINJRegulatory | Phase 2 |
| Terminated | Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma NCT01875653 | Lisata Therapeutics, Inc. | Phase 3 |
| Completed | Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma NCT02107755 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Completed | Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma NCT02073123 | NewLink Genetics Corporation | Phase 1 / Phase 2 |
| Terminated | Immunotherapy Study for Patients With Stage IV Melanoma NCT02054520 | NewLink Genetics Corporation | Phase 2 |
| Completed | Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic NCT02094872 | Yale University | Phase 2 |
| Completed | Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot B NCT02013492 | William Carson | EARLY_Phase 1 |
| Terminated | Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or NCT01835184 | National Cancer Institute (NCI) | Phase 1 |
| Completed | LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in NCT01726738 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Completed | Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma NCT01703507 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |
| Completed | Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery NCT01748747 | Mayo Clinic | EARLY_Phase 1 |
| Terminated | FDG-PET in Advanced Melanoma NCT02236546 | Vanderbilt-Ingram Cancer Center | N/A |
| Withdrawn | Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma NCT02507076 | Albert Einstein College of Medicine | N/A |
| Completed | Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Me NCT01339663 | Fred Hutchinson Cancer Center | Phase 1 |
| Withdrawn | Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma NCT00979693 | Multidisciplinary Association for Psychedelic Studies | Phase 2 |
| Terminated | Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery NCT01533948 | Roswell Park Cancer Institute | Phase 2 |
| Terminated | Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior NCT01519427 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma NCT01316692 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Completed | Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma NCT01376713 | Medical University of Vienna | Phase 2 |
| Completed | Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery NCT01328535 | Mayo Clinic | Phase 2 |
| Terminated | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma NCT01120275 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Mel NCT01026051 | Mannkind Corporation | Phase 2 |
| Terminated | Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV NCT01166126 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surger NCT01216787 | National Cancer Institute (NCI) | Phase 2 |
| Completed | An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Sta NCT01136967 | Eisai Inc. | Phase 2 |
| Completed | Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanom NCT01107665 | University of California, Irvine | Phase 2 |
| Unknown | Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. NCT01168050 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Completed | Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma NCT01127451 | Eisai Inc. | Phase 2 |
| Completed | E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients NCT01133977 | Eisai Inc. | Phase 1 / Phase 2 |
| Terminated | Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Mel NCT01106235 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma NCT01103635 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Completed | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer NCT01037790 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Completed | LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma NCT01010984 | Robert C. Martin | N/A |
| Terminated | Dinaciclib in Treating Patients With Stage III-IV Melanoma NCT01026324 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung NCT00937482 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-I NCT00945269 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma NCT00871481 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma NCT00726739 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Viral Therapy in Treating Patients With Metastatic Melanoma NCT00651157 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma NCT00553306 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Ca NCT00281957 | National Cancer Institute (NCI) | Phase 2 |
| Completed | VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery NCT00450255 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03) NCT00438009 | Viralytics | Phase 1 |
| Completed | Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other NCT00498979 | Case Comprehensive Cancer Center | Phase 1 |
| Completed | Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery NCT00470470 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melan NCT00438984 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Phase 1 |
| Terminated | A Study of Volociximab in Metastatic Melanoma NCT00369395 | Abbott | Phase 2 |
| Completed | Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma NCT00436605 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery NCT00669019 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma NCT01851408 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma NCT00349206 | National Cancer Institute (NCI) | Phase 1 |
| Completed | AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma NCT00243061 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By NCT00255762 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion i NCT00303836 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma NCT00288041 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma NCT00121225 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Sta NCT00217542 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery NCT00119249 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors NCT00112476 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors NCT00655655 | Mayo Clinic | Phase 1 |
| Terminated | A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma NCT00199342 | Kyowa Kirin, Inc. | Phase 1 / Phase 2 |
| Completed | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Vaccine Therapy in Treating Patients With Metastatic Melanoma NCT00087373 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma NCT00089063 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Tanespimycin in Treating Patients With Stage III-IV Melanoma NCT00087386 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma NCT00085189 | University of Southern California | Phase 2 |
| Completed | Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma NCT00085306 | Case Comprehensive Cancer Center | Phase 2 |
| Terminated | Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma NCT00082875 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | A Phase II Study of UCN-01 in Metastatic Melanoma NCT00072189 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma NCT00072163 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers NCT00074308 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Tipifarnib in Treating Patients With Metastatic Malignant Melanoma NCT00060125 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leuke NCT00039091 | National Cancer Institute (NCI) | Phase 1 |
| Completed | BMS-247550 in Treating Patients With Stage IV Melanoma NCT00036764 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Disulfiram in Patients With Metastatic Melanoma NCT00256230 | John P. Fruehauf | Phase 1 / Phase 2 |
| Completed | Decitabine in Treating Patients With Advanced Solid Tumors NCT00030615 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma NCT00026143 | National Cancer Institute (NCI) | Phase 2 |
| Completed | PS-341 in Treating Patients With Metastatic Malignant Melanoma NCT00024011 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma NCT00005949 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma NCT00006243 | National Cancer Institute (NCI) | N/A |
| Terminated | SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated NCT00006003 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma NCT00003552 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma NCT00019448 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma NCT00003646 | Vical | Phase 2 |
| Completed | Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma NCT00003647 | Vical | Phase 3 |
| Completed | flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer NCT00019396 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Antineoplaston Therapy in Treating Patients With Stage IV Melanoma NCT00003509 | Burzynski Research Institute | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma NCT00019890 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positiv NCT02145910 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |